In contrast, the S1P2 inhibitor JTE-013 was shown to additionally antagonize S1P4, which was not expressed in GBM cells in our study, however additional off-target effects of JTE-013 cannot be excluded [36]. This evidence concerns the gene S1PR4 and glioblastoma.